Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer

被引:0
作者
Madeleine B. Hopson
Shing Lee
Melissa Accordino
Meghna Trivedi
Matthew Maurer
Katherine D. Crew
Dawn L. Hershman
Kevin Kalinsky
机构
[1] Columbia University Irving Medical Center,Mailman School of Public Health
[2] Columbia University,Herbert Irving Comprehensive Cancer Center
[3] Columbia University,undefined
[4] Bristol-Myers Squibb,undefined
[5] Winship Cancer Institute at Emory University,undefined
来源
Breast Cancer Research and Treatment | 2021年 / 188卷
关键词
Breast Cancer; Propranolol; Angiogenesis; Neoadjuvant chemotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:427 / 432
页数:5
相关论文
共 104 条
[1]  
Weidner N(1992)Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1875-1887
[2]  
Folkman J(2004)Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis Cancer Res 64 2941-2955
[3]  
Pozza F(2003)E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer Clin Breast Cancer 3 421-422
[4]  
Uzzan B(2011)Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO Eur J Cancer 47 2387-2395
[5]  
Nicolas P(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer J Clin Oncol 70 7042-7052
[6]  
Cucherat M(2010)The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 12 939-944
[7]  
Perret GY(2006)Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 15 2042-2052
[8]  
Miller KD(2008)Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 29 2645-2652
[9]  
Pivot X(2011)Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Breast Cancer Res Treat 26 1781-1783
[10]  
Schneeweiss A(2011)Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 1 628-38